Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

ClinicalTrials.gov ID: NCT00504270

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00504270. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 12:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis. Patients will be randomized to one of 3 treatment groups to receive once daily oral treatment with a)R3421 20mg, b)R3421 120mg, or c)placebo. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.

Study identification

NCT ID
NCT00504270
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
66 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 2007 (Type not available)
Primary completion
Sep 2009 (Actual)
Completion
Sep 2009 (Actual)
Last update posted
Nov 2, 2016

2007 – 2009

United States locations

U.S. sites
15
U.S. states
10
U.S. cities
14
Facility City State ZIP Site status
Not listed Hot Springs Arkansas 71913 —
Not listed Little Rock Arkansas 72205 —
Not listed Santa Monica California 90404 —
Not listed Alpharetta Georgia 30005 —
Not listed East Windsor New Jersey 08520 —
Not listed Albuquerque New Mexico 87106 —
Not listed New York New York 10016 —
Not listed New York New York 10029 —
Not listed Stony Brook New York 11790 —
Not listed Winston-Salem North Carolina 27157 —
Not listed Providence Rhode Island 02903 —
Not listed Nashville Tennessee 37215 —
Not listed Galveston Texas 77550 —
Not listed San Antonio Texas 78229 —
Not listed Webster Texas 77598 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00504270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 2, 2016 · Synced Nov 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.